GlassScriptPhysician profile
Mina A Vanrachack
NPI 1033687058
$5,184.85
in general payments reported to CMS, 2019-2025
30 companies · $808 in 2025
The $808 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $281 · 2021: $421 · 2022: $872 · 2023: $1,035 · 2024: $942 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Entertainment: $42.25 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.43 |
| Entertainment | $42.25 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $994.59 | 2019-2025 | |
| Portola Pharmaceuticals, LLC | $472.53 | 2019 | |
| Abbvie INC. | $414.73 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $392.81 | 2021-2025 | Cequa |
| Amgen INC. | $299.98 | 2024-2025 | Tepezza |
| Glaukos Corporation | $280.44 | 2019-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Photrexa Cross-Linking Kit |
| Johnson & Johnson Surgical Vision, INC. | $234.42 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $216.91 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $205.89 | 2021-2024 | Oxervate |
| Rxsight INC | $201.42 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Harrow Eye, LLC | $182.59 | 2024-2025 | Vevye, Iheezo |
| Novartis Pharmaceuticals Corporation | $149.08 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.33 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $137.88 | 2020-2021 | |
| Lkc Technologies, INC. | $132.24 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.99 | 2022 | |
| Oyster Point Pharma, INC. | $108.92 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $81.93 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $65.66 | 2019-2020 | |
| Thea Pharma INC. | $47.91 | 2023-2024 | |
| Shire North American Group INC | $45.36 | 2019 | |
| Allergan, INC. | $43.74 | 2022 | |
| Optos, INC. | $42.25 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $35.32 | 2022-2023 | Eysuvis |
| Ani Pharmaceuticals, INC. | $33.91 | 2024 | Purified Cortrophin Gel |
| Staar Surgical Company | $25.78 | 2019 | |
| Tearlab Corp | $24.85 | 2023 | Tearlab Osmolarity System |
| Ocular Therapeutix, INC. | $20.98 | 2024 | Dextenza |
| Oasis Medical, INC. | $16.25 | 2022 | |
| Quidel Corporation | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$107.34 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Vanrachack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.